<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04651972</url>
  </required_header>
  <id_info>
    <org_study_id>2020PI116</org_study_id>
    <nct_id>NCT04651972</nct_id>
  </id_info>
  <brief_title>Measurement of vanilloïd Compounds in Urin of Autistic vs Control Patients, as Potential Biomarkers</brief_title>
  <acronym>DIADAUVEDA</acronym>
  <official_title>Diagnostic of Autism by Measurement of vanilloïd Compounds in Urin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a former study, four vanilloid compounds were observed increased in the urin of autistic&#xD;
      patients. The present study is aimed at performing a ambispective study to confirm or not&#xD;
      these preliminary results. 70 urins from autistic children (already collected) will be&#xD;
      compared to 70 urins of non autistic children (collected without intervention, remaining&#xD;
      sample from the standard care), in terms of measurements of four vanilloid compounds using a&#xD;
      GCMS apparatus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>measurements of vanilloid compound in urins</measure>
    <time_frame>through study completion, an average of 18 months</time_frame>
    <description>The primary end point is to determine if isolated or combinations of vanilloid compound measured in urin, may discriminate autistic vs non autistic childen</description>
  </primary_outcome>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      urines&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Autistic children according to CM-10 (F84.0)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
        For cases :&#xD;
&#xD;
          -  Male children aged 2 years to less than 15 years inclusive years at time of sample&#xD;
             collection&#xD;
&#xD;
          -  Children with a diagnosis of autism (ICD-10 F84.0) after assessment by a child&#xD;
             psychiatrist.&#xD;
&#xD;
        For healthy chlidren:&#xD;
&#xD;
          -  Children aged 2 years to less than 15 years old performing an ECBU at the CHRU of&#xD;
             Nancy as part of their care.&#xD;
&#xD;
          -  Patient whose ECBU is negative with respect to cytobacteriology (absence of urinary&#xD;
             infection).&#xD;
&#xD;
          -  Child can be matched to a CAS&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        For cases:&#xD;
&#xD;
          -  Children in whom one of the following pathologies is found during the anamnesis or in&#xD;
             the clinical record : (i) renal insufficiency; (ii) urinary tract infection at the&#xD;
             time of sampling and/or metabolic disease&#xD;
&#xD;
          -  Children on antibiotic treatment at the time of collection&#xD;
&#xD;
        For healthy chlidren :&#xD;
&#xD;
          -  children whose urine culture come from one of the following departments: Pediatric&#xD;
             Nephrology (potential risk of renal failure) or Pediatric Neurology (potential risk of&#xD;
             neurological disorder).&#xD;
&#xD;
          -  with a diagnosis of autism&#xD;
&#xD;
          -  with a metabolic disease&#xD;
&#xD;
          -  children undergoing antibiotic treatment at the time of collectio&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>only males will be studied</gender_description>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Luc Olivier, MD, PhD,</last_name>
    <role>Study Director</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Merten, PhD</last_name>
    <phone>33 616 364 916</phone>
    <email>m.merten@chru-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Luc Olivier, MD, PhD, Pr</last_name>
    <email>jl.olivier@chru-nancy.fr</email>
  </overall_contact_backup>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Marc MERTEN</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

